MOUNTAIN VIEW, Calif., Sept. 17, 2015 /PRNewswire/ --
| WHEN: |
11:00 a.m. EDT on Tuesday, September 22, 2015 |
| LOCATION: |
Online, with free registration (Email kayla.belcher@frost.com) |
| EXPERT PANELIST: |
Frost & Sullivan Senior Consultant Jane Andrews |
Cell therapy is the fastest growing segment of regenerative medicine, the majority of which is stem cell therapy. It is estimated the global stem cell therapy market will reach $40 billion by 2020 and $180 billion by 2030.
Many factors determine the rate at which the stem cell therapy market advances. It is driven by documented successes and research indicating the potential of stem cell treatments to cure life-threatening diseases such as cancer, heart diseases and neuromuscular diseases in the world's aging populations.
In contrast, the stem cell market growth rate is hindered by manufacturing and regulatory concerns. For example, if only 20 percent of the 318 global late-stage clinical trials are approved for release on the market, there will not be enough stem cell therapy manufacturing facilities to produce the 64 resulting products. This is due, in part, to funding concerns, the high cost of build-out, as well as cGMP compliance, standardization of production processes and industry regulation changes.
The analyst briefing will explore successful stem cell therapy treatments and marketed products within the industry. It will consider the stem cell therapy pipeline, including phases of clinical trials and leading indications in addition to manufacturing considerations.
Attend this webinar to discover tangible insights on:
This presentation is directed towards strategy specialists and service providers as well as investor groups looking for emerging opportunities within the segment of regenerative medicine.
Thought leader insights:
"Stem cell therapy is a new and rapidly growing industry showing phenomenal potential in its ability to be operated alone or in combination with gene and immunotherapy to cure diseases," said Frost & Sullivan's Transformational Health Senior Consultant, Jane Andrews. "A key barrier to market growth is manufacturing. Aside from regulatory concerns, it is difficult to efficiently scale up production. The cost of goods sold for autologous production is very high, and practical quality process engineering is badly needed for both autologous and allogeneic production to increase profit margins to acceptable levels."
Register:
To attend the briefing, email Kayla Belcher, Corporate Communications – kayla.belcher@frost.com - your full name, job title, company name, company telephone number, and company email address, website, city, state and country, or click here: http://bit.ly/1Ko0AzG.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.
Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
Contact Us: Start the discussion
Subscribe: Newsletter on "the next big thing"
Register: Gain access to visionary innovation
Contact:
Kayla Belcher
Corporate Communications - North America
+1.210.247.2450
kayla.belcher@frost.com
Logo - http://photos.prnasia.com/prnh/20140910/8521405145LOGO
